The “V” Vaccine Aids in Recovery for Melanoma Patients
Dr. James Mulé is the Executive Vice President for Translational Research and the Michael McGillicuddy Endowed Chair for Melanoma at the Moffitt Cancer Center in Tampa, FL. Dr. Mulé received a $1 million designated grant from The V Foundation in 2007 to support research about melanoma. The grant has allowed Dr. Mulé to explore immune-based therapies and tumor vaccines.
Skin cancer is the most common type of all cancers, and the number of skin cancer cases continues to rise in the U.S. to over one million diagnoses each year. Dr. Mulé leads a team of skin cancer researchers at Moffit that look into vaccine strategies and other approaches to stimulate the immune system and destroy tumors. Dr. Mulé has developed a “V” vaccine to help melanoma patients. “The generous funding of The V Foundation allowed us to develop and launch the very first therapeutic vaccine of its kind in melanoma patients that creates new, functioning lymph nodes in the body,” said Dr. Mulé.
The V vaccine is expected to set the stage for vaccines that will boost immunity to a variety of cancer types.
Your support of The V Foundation allows our researchers to make huge strides in the fight against cancer. Thanks for being a part of The V Team!